Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.57 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.57 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.53 |
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041088 | 1.00 | NOD1 (0.57) | NOD1PLA2G2CPLA2G10GLP1RFAAH | |
| SCHEMBL10888303 | 0.92 | NOD1 (0.60) | NOD1PLA2G2CGLP1RFAAHMEN1 | |
| SCHEMBL6931475 | 0.89 | NOD1 (0.60) | NOD1PLA2G2CPLA2G10GLP1R | |
| SCHEMBL6809578 | 0.87 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GLP1RFAAH | |
| SCHEMBL9517290 | 0.87 | GLP1R (0.61) | NOD1PLA2G2CGLP1R | |
| SCHEMBL27935271 | 0.87 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GLP1RFAAH | |
| SCHEMBL9441752 | 0.87 | GLP1R (0.61) | NOD1PLA2G2CGLP1R | |
| SCHEMBL28719000 | 0.84 | NOD1 (0.61) | NOD1PLA2G2CPLA2G10FAAHMEN1 | |
| SCHEMBL28715914 | 0.84 | NOD1 (0.61) | NOD1PLA2G2CPLA2G10FAAHMEN1 | |
| SCHEMBL28705590 | 0.84 | NOD1 (0.61) | NOD1PLA2G2CPLA2G10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-6011007-A | ZN2+ COMPLEX. | NOVO NORDISK A/S (DK) | 2000-01-04 | — | — | US | claimed |
| US-10195254-B2 | Myristoylated leptin-related peptides and uses thereof | ALBANY MEDICAL COLLEGE (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170312340-A1 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2017-11-02 | — | — | US | disclosed |
| CN-106794225-A | Leptin related peptide of myristoylation and application thereof | 奥尔巴尼医学院 | 2017-05-31 | — | — | CN | disclosed |
| US-20060030518-A1 | Acylated insulin | SCIAPS, INC. | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030518-A1 | Acylated insulin | INSR, BCAT1, SLC1A5 | NOD1 2995/4885PLA2G2C 538/4885PLA2G10 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.